Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor
about
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentEmerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the RatAntibody Drug Conjugates: Nonclinical Safety Considerations.Clinical pharmacology of bispecific antibody constructs.Cell surface dynamics and cellular distribution of endogenous FcRn.Quantification of IgG monoclonal antibody clearance in tissues.Impact of altered endogenous IgG on unspecific mAb clearance.Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy.Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.Acute Treatment With XMetA Activates Hepatic Insulin Receptors and Lowers Blood Glucose in Normal Mice.TriFabs--Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery.A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.Capacity limits of asialoglycoprotein receptor-mediated liver targeting.ADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds
P2860
Q28082880-B6E93724-DEA7-472D-9FD6-022A16C61633Q33838871-68D7F8F9-BC59-4D98-B3B7-E8BEDE8DAAB9Q35768430-F3D670B5-2127-4448-A275-443E0E018226Q35967917-DEE8F957-DABA-45E8-8B10-A1BCF8DAAF9FQ38364459-0220163D-B429-43E1-A795-64CC1986298CQ38619824-53EF5754-9AA6-4633-940D-67C682DDC820Q38726179-B445CF24-AB47-4197-B5DA-6A1490846580Q38821722-19B06B23-106D-4436-9235-860A53CA96BBQ39271075-DA381094-95BF-49CF-B342-E0C16C505189Q39731345-0AFA5624-0DAA-41CD-AD26-D0FDACBE226CQ39830501-85A097F5-8A4D-4FBD-8606-EB3F95198988Q41161575-B43D76AB-837B-4D9C-ACF0-2B42B894A17CQ41924939-4FCB110C-35EC-4AF9-B04E-44E94D4B134DQ46242399-5BF55175-C208-4A82-A5D4-F10774CDDBECQ50216455-AAA2CB51-BC8C-4523-99A5-EAD13BB8B7D2Q58869554-0F584387-BCFB-44DA-B549-4FB9EF775E46
P2860
Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Quantitative cumulative biodis ...... ty to the neonatal Fc receptor
@ast
Quantitative cumulative biodis ...... ty to the neonatal Fc receptor
@en
Quantitative cumulative biodis ...... y to the neonatal Fc receptor.
@nl
type
label
Quantitative cumulative biodis ...... ty to the neonatal Fc receptor
@ast
Quantitative cumulative biodis ...... ty to the neonatal Fc receptor
@en
Quantitative cumulative biodis ...... y to the neonatal Fc receptor.
@nl
prefLabel
Quantitative cumulative biodis ...... ty to the neonatal Fc receptor
@ast
Quantitative cumulative biodis ...... ty to the neonatal Fc receptor
@en
Quantitative cumulative biodis ...... y to the neonatal Fc receptor.
@nl
P2093
P2860
P356
P1476
Quantitative cumulative biodis ...... ty to the neonatal Fc receptor
@en
P2093
Ben Q Shen
Daniela Bumbaca
Devin B Tesar
Eduardo E Mundo
Elizabeth K Torres
Enzo Palma
Leslie A Khawli
Noe A Reyes
Paul J Fielder
Saileta Prabhu
P2860
P304
P356
10.4161/MABS.28254
P50
P577
2014-02-26T00:00:00Z